Skip to main content

Table 1 Patient’s baseline clinical characteristics and comparisons between the training and validation groups

From: A novel nomogram to stratify quality of life among advanced cancer patients with spinal metastatic disease after examining demographics, dietary habits, therapeutic interventions, and mental health status

Characteristics

Patients (n = 208)

Training group (n = 104)

Validation group (n = 104)

P

Age (mean ± SD, years)

58.74 ± 12.00

58.12 ± 12.15

59.36 ± 11.88

0.46 a

Sex

   

0.68

 Male

51.44% (107/208)

50.00% (52/104)

52.88% (55/104)

 

 Female

48.56% (101/208)

50.00% (52/104)

47.12% (49/104)

 

Nationality

   

0.70

 Han nationality

96.63% (201/208)

96.15% (100/104)

97.12% (101/104)

 

 Ethnic minorities

3.37% (7/208)

3.85% (4/104)

2.88% (3/104)

 

Marital status

   

0.58

 Married

93.27% (194/208)

92.31% (96/104)

94.23% (98/104)

 

 Single

6.73% (14/208)

7.69% (8/104)

5.77% (6/104)

 

Education

    

 Primary education

35.58% (74/208)

35.58% (37/104)

35.58% (37/104)

0.69

 Senior high school

35.10% (73/208)

32.69% (34/104)

37.50% (39/104)

 

 University or above

29.33% (61/208)

31.73% (33/104)

26.92% (28/104)

 

Caregivers

   

0.90

 Spouse

64.90% (135/208)

64.42% (67/104)

65.38% (68/104)

 

 Other family members

18.75% (39/208)

19.23% (20/104)

18.27% (19/104)

 

 Support workers

4.81% (10/208)

5.77% (6/104)

3.85% (4/104)

 

 No caregivers

11.54% (24/208)

10.58% (11/104)

12.50% (13/104)

 

Preference for eating vegetables

   

0.68

 No

13.46% (28/208)

14.42% (15/104)

12.50% (13/104)

 

 Yes

86.54% (180/208)

85.58% (89/104)

87.50% (91/104)

 

Preference for eating roasted food

   

0.64

 No

90.38% (188/208)

91.35% (95/104)

89.42% (93/104)

 

 Yes

9.62% (20/208)

8.65% (9/104)

10.58% (11/104)

 

Smoking status

   

0.30

 No

57.21% (119/208)

62.50% (65/104)

51.92% (54/104)

 

 Quitting smoking

23.56% (49/208)

21.15% (22/104)

25.96% (27/104)

 

 Current smoking

19.23% (40/208)

16.35% (17/104)

22.12% (23/104)

 

Drinking status

   

0.03

 No

73.56% (153/208)

76.92% (80/104)

70.19% (73/104)

 

 Quitting drinking

18.75% (39/208)

12.50% (13/104)

25.00% (26/104)

 

 Current drinking

7.69% (16/208)

10.58% (11/104)

4.81% (5/104)

 

Hypertension

   

0.02

 No

75.48% (157/208)

82.69% (86/104)

68.27% (71/104)

 

 Yes

24.52% (51/208)

17.31% (18/104)

31.73% (33/104)

 

Diabetes

   

0.64

 No

90.38% (188/208)

89.42% (93/104)

91.35% (95/104)

 

 Yes

9.62% (20/208)

10.58% (11/104)

8.65% (9/104)

 

Coronary heart disease

   

0.30

 No

92.31% (192/208)

94.23% (98/104)

90.38% (94/104)

 

 Yes

7.69% (16/208)

5.77% (6/104)

9.62% (10/104)

 

Time since knowing cancer diagnosis

   

0.05

  < 3 months

17.79% (37/208)

15.38% (16/104)

20.19% (21/104)

 

 ≧3 months and < 6 months

10.10% (21/208)

7.69% (8/104)

12.50% (13/104)

 

 ≧6 months and < 12 months

10.10% (21/208)

15.38% (16/104)

4.81% (5/104)

 

 ≧12 months

62.02% (129/208)

61.54% (64/104)

62.50% (65/104)

 

Primary cancer type

   

0.13

 Lung cancer

57.21% (119/208)

50.96% (53/104)

63.46% (66/104)

 

 Liver cancer

4.81% (10/208)

3.85% (4/104)

5.77% (6/104)

 

 Gastrointestinal cancer

7.69% (16/208)

7.69% (8/104)

7.69% (8/104)

 

 Breast cancer

9.62% (20/208)

9.62% (10/104)

9.62% (10/104)

 

 Others

20.67% (43/208)

27.88% (29/104)

13.46% (14/104)

 

Visceral metastases

   

1.00

 No

56.73% (118/208)

56.73% (59/104)

56.73% (59/104)

 

 Yes

43.27% (90/208)

43.27% (45/104)

43.27% (45/104)

 

Surgery for primary cancer site

   

0.13

 Open surgery

19.71% (41/208)

25.00% (26/104)

14.42% (15/104)

 

 Minimally invasive surgery

20.67% (43/208)

21.15% (22/104)

20.19% (21/104)

 

 None

59.62% (124/208)

53.85% (56/104)

65.38% (68/104)

 

Surgery for spine metastasis

   

0.63

 Open surgery

15.87% (33/208)

18.27% (19/104)

13.46% (14/104)

 

 Minimally invasive surgery

54.81% (114/208)

52.88% (55/104)

56.73% (59/104)

 

 None

29.33% (61/208)

28.85% (30/104)

29.81% (31/104)

 

Radiotherapy

   

0.26

 No

39.42% (82/208)

35.58% (37/104)

43.27% (45/104)

 

 Yes

60.58% (126/208)

64.42% (67/104)

56.73% (59/104)

 

Chemotherapy

   

0.09

 No

39.42% (82/208)

33.65% (35/104)

45.19% (47/104)

 

 Yes

60.58% (126/208)

66.35% (69/104)

54.81% (57/104)

 

Economic burden due to cancer treatments

   

0.83

 None

2.88% (6/208)

2.88% (3/104)

2.88% (3/104)

 

 Mild

10.58% (22/208)

8.65% (9/104)

12.50% (13/104)

 

 Moderate

32.21% (67/208)

33.65% (35/104)

30.77% (32/104)

 

 Severe

54.33% (113/208)

54.81% (57/104)

53.85% (56/104)

 

Having an uncompleted life goal

   

0.52

 No

24.04% (50/208)

22.12% (23/104)

25.96% (27/104)

 

 Yes

75.96% (158/208)

77.88% (81/104)

74.04% (77/104)

 

ECOG score

   

0.54

 0

6.73% (14/208)

6.73% (7/104)

6.73% (7/104)

 

 1

34.13% (71/208)

35.58% (37/104)

32.69% (34/104)

 

 2

29.81% (62/208)

31.73% (33/104)

27.88% (29/104)

 

 3

11.54% (24/208)

7.69% (8/104)

15.38% (16/104)

 

 4

17.79% (37/208)

18.27% (19/104)

17.31% (18/104)

 

Anxiety

   

0.69

 No

47.60% (99/208)

46.15% (48/104)

49.04% (51/104)

 

 Skeptical

20.67% (43/208)

23.08% (24/104)

18.27% (19/104)

 

 Yes

31.73% (66/208)

30.77% (32/104)

32.69% (34/104)

 

Depression

   

0.30

 No

51.44% (107/208)

51.92% (54/104)

50.96% (53/104)

 

 Skeptical

19.23% (40/208)

15.38% (16/104)

23.08% (24/104)

 

 Yes

29.33% (61/208)

32.69% (34/104)

25.96% (27/104)

 

FACT-G scores

60.32 ± 20.41

60.83 ± 20.18

59.82 ± 20.73

0.85 b

 Physical well-being

14.41 ± 7.22

14.23 ± 7.35

14.60 ± 7.11

0.70 b

 Social well-being

18.62 ± 5.82

18.90 ± 5.63

18.33 ± 6.02

0.51 b

 Emotional well-being

14.24 ± 5.7

14.20 ± 5.58

14.28 ± 5.84

0.99 b

 Functional well-being

13.05 ± 7.14

13.49 ± 7.48

12.62 ± 6.78

0.42 b

  1. SD standard deviation, ECOG eastern cooperative oncology group, FACT-G functional assessment of cancer therapy-general
  2. aindicates the student’s t test
  3. bindicates the Wilcoxon two-sample test